Jailer JW & Holub DA. Remission of Grave’s disease following radiotherapy of a pituitary neoplasm. American Journal of Medicine. 1960; 28: 497–500.
Brucker Davis F, Oldfield E, Skarulis M, Doppman JL & Weintraub BD. Thyrotropin-secreting pituitary tumours: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 476–86.
Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;.148:433-42
Kienitz T, Quinkler M, Strasburger CJ, Ventz M Longterm management in five cases of TSHsecreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007; 157: 39-46.
Françoise Brucker-Davis, Edward H. Oldfield, Monica C. Skarulis, John L. Doppman, and Bruce D.Weintraub. Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health. JCEM.1999; 84:476-86
Chanson P, Li JY, LeDafniet M, et al. Absence of receptors for thyrotropin (TSH)-releasing hormone in human TSH-secreting pituitary adenomas associated with hyperthyroidism. J Clin Endocrinol Metab. 1988;.66:447–50
Saad B, Liu A, Brucker-Davis F, Spencer C, LoPresti J, Nicoloff J. Simplified screening test for resistance to thyroid hormone (RTH)–the T3 challenge test (T3CT) [Abstract P1–396]. Proc of the 77th Annual Meet of The Endocrine Soc. 1995; 211: 207-12
Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone α-subunit in pituitary adenomas.Trends Endocrinol Metab. 1992; 3:41–5.
Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med.1994;120:817–20.
Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord. 2009 ;10:111-23. Review .
Yazışma Adresi / Address for Correspondence: Dr. Okan Bakıner Başkent Üniversitesi Adana Uygulama ve Araştırma Merkezi Endokrinoloji A nabilim Dalı Yüreğir-ADANA e-mail: okanbakiner@mynet.com geliş tarihi/received :27.12.2012 kabul tarihi/accepted:04.01.2013
Jailer JW & Holub DA. Remission of Grave’s disease following radiotherapy of a pituitary neoplasm. American Journal of Medicine. 1960; 28: 497–500.
Brucker Davis F, Oldfield E, Skarulis M, Doppman JL & Weintraub BD. Thyrotropin-secreting pituitary tumours: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. Journal of Clinical Endocrinology and Metabolism. 1999; 84: 476–86.
Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;.148:433-42
Kienitz T, Quinkler M, Strasburger CJ, Ventz M Longterm management in five cases of TSHsecreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007; 157: 39-46.
Françoise Brucker-Davis, Edward H. Oldfield, Monica C. Skarulis, John L. Doppman, and Bruce D.Weintraub. Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health. JCEM.1999; 84:476-86
Chanson P, Li JY, LeDafniet M, et al. Absence of receptors for thyrotropin (TSH)-releasing hormone in human TSH-secreting pituitary adenomas associated with hyperthyroidism. J Clin Endocrinol Metab. 1988;.66:447–50
Saad B, Liu A, Brucker-Davis F, Spencer C, LoPresti J, Nicoloff J. Simplified screening test for resistance to thyroid hormone (RTH)–the T3 challenge test (T3CT) [Abstract P1–396]. Proc of the 77th Annual Meet of The Endocrine Soc. 1995; 211: 207-12
Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone α-subunit in pituitary adenomas.Trends Endocrinol Metab. 1992; 3:41–5.
Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann Intern Med.1994;120:817–20.
Colao A, Pivonello R, Di Somma C, Savastano S, Grasso LF, Lombardi G. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord. 2009 ;10:111-23. Review .
Yazışma Adresi / Address for Correspondence: Dr. Okan Bakıner Başkent Üniversitesi Adana Uygulama ve Araştırma Merkezi Endokrinoloji A nabilim Dalı Yüreğir-ADANA e-mail: okanbakiner@mynet.com geliş tarihi/received :27.12.2012 kabul tarihi/accepted:04.01.2013